News

Find us here ...

Subscribe to our newsletter

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.

No spam - just the good stuff

More

News

News

Researchers land $3.2m to study impact of microbiome disruption on Alzheimer’s

Crucible Therapeutics spins out with £5m for neurodegenerative disease gene therapies

Vivante gobbles up $31m for digestive health tech

Genflow makes progress towards clinical trial of NASH gene therapy

FDA clears AI tool for early Alzheimer’s detection from MRI scans

Broken String snags $15 million to make cell and gene therapy safer

FDA greenlights Beacon’s AI-assisted sleep monitoring device

Carenostics raises $5m for AI-powered chronic disease diagnosis

Sonera exits stealth with $11m for neural sensing chip technology

Find us here ...

Subscribe to our newsletter

More